SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo.
SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo.
复制标题
SOMCL-863 是一种新型、选择性、口服生物可利用的小分子 c-Met 抑制剂,在体外和体内均表现出抗肿瘤活性。
DOI:
10.1016/j.canlet.2014.05.012
复制
发表时间:
2014-08
期刊:
影响因子:
--
通讯作者:
Geng Meiyu
中科院分区:
文献类型:
--
作者:
Huang Min;Zhang AO;Ding Jian;Geng Meiyu
Deregulation of HGF/c-Met signaling and its driven neoplastic phenotype are associated with a variety of human malignancies. We herein reported SOMCL-863 as a novel selective c-Met inhibitor which effectively abrogated c-Met signaling pathways, thereby leading to substantial impairment of c-Met-dependent cell proliferation, migration, invasion, cell scattering and invasive growth. In EBC-1 and NCI-H1993 xenografts, SOMCL-863 exerted significant anti-tumor efficacy through anti-proliferative effects and antiangiogenic mechanisms, including reduction of tumor cell proliferation and reductions of microvessel density and secretion of proangiogenic factor IL-8. Together with the optimal pharmacokinetic properties, SOMCL-863 is a promising candidate worthy for further evaluation as a treatment of c-Met-driven human cancers.
登录
查看更多内容
影响因子:
7.3
作者:
Yuanxiang Wang;Jing Ai;Ying Wang;Yi Chen;Lu Wang;Gang Liu;M. Geng;Ao Zhang
通讯作者:
Yuanxiang Wang;Jing Ai;Ying Wang;Yi Chen;Lu Wang;Gang Liu;M. Geng;Ao Zhang
影响因子:
11.2
作者:
G. Dong;Zhong Chen;Zhi-yu Li;N. Yeh;C. Bancroft;C. Waes
通讯作者:
G. Dong;Zhong Chen;Zhi-yu Li;N. Yeh;C. Bancroft;C. Waes
DOI:
10.1073/pnas.0508776103
发表时间:
2006-02-14
影响因子:
11.1
作者:
Smolen, GA;Sordella, R;Haber, DA
通讯作者:
Haber, DA
影响因子:
8.2
作者:
Wang, Xiao-lei;Chen, Xi-mei;Yang, Chang-qin
通讯作者:
Yang, Chang-qin
影响因子:
8.2
作者:
He, Chang-xi;Ai, Jing;Geng, Mei-yu
通讯作者:
Geng, Mei-yu